148 related articles for article (PubMed ID: 32562630)
1. Neurofibromatosis type 1-related tumours in paediatrics: an evolving treatment landscape.
Armstrong AE; Brossier NM; Hirbe AC
Lancet Child Adolesc Health; 2020 Jul; 4(7):488-490. PubMed ID: 32562630
[No Abstract] [Full Text] [Related]
2. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
Gottfried ON; Viskochil DH; Couldwell WT
Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
[TBL] [Abstract][Full Text] [Related]
3. Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients.
Ars E; Kruyer H; Morell M; Pros E; Serra E; Ravella A; Estivill X; Lázaro C
J Med Genet; 2003 Jun; 40(6):e82. PubMed ID: 12807981
[No Abstract] [Full Text] [Related]
4. Translating current basic research into future therapies for neurofibromatosis type 1.
Brosseau JP; Liao CP; Le LQ
Br J Cancer; 2020 Jul; 123(2):178-186. PubMed ID: 32439933
[TBL] [Abstract][Full Text] [Related]
5. Therapy for plexiform neurofibromas in children with neurofibromatosis 1: an overview.
Packer RJ; Rosser T
J Child Neurol; 2002 Aug; 17(8):638-41; discussion 646-51. PubMed ID: 12403563
[TBL] [Abstract][Full Text] [Related]
6. Neurofibromatosis type 1 (NF1): diagnosis and management.
Ferner RE; Gutmann DH
Handb Clin Neurol; 2013; 115():939-55. PubMed ID: 23931823
[TBL] [Abstract][Full Text] [Related]
7. Neurofibromatosis in the Era of Precision Medicine: Development of MEK Inhibitors and Recent Successes with Selumetinib.
Galvin R; Watson AL; Largaespada DA; Ratner N; Osum S; Moertel CL
Curr Oncol Rep; 2021 Mar; 23(4):45. PubMed ID: 33721151
[TBL] [Abstract][Full Text] [Related]
8. Determination of end points for treatment of neurofibromatosis 1.
Korf BR
J Child Neurol; 2002 Aug; 17(8):642-5; discussion 646-51. PubMed ID: 12403564
[TBL] [Abstract][Full Text] [Related]
9. Targeted genetic and molecular therapies in neurofibromatosis - A review of present therapeutic options and a glimpse into the future.
Feroze K; Kaliyadan F
Indian J Dermatol Venereol Leprol; 2021; 88(1):1-10. PubMed ID: 34379966
[TBL] [Abstract][Full Text] [Related]
10. Nerve sheath tumours.
Robertson JA; Tallantyre EC
J Neurol; 2018 Dec; 265(12):3034-3035. PubMed ID: 30382390
[No Abstract] [Full Text] [Related]
11. Early administration of imatinib mesylate reduces plexiform neurofibroma tumor burden with durable results after drug discontinuation in a mouse model of neurofibromatosis type 1.
Armstrong AE; Rhodes SD; Smith A; Chen S; Bessler W; Ferguson MJ; Jiang L; Li X; Yuan J; Yang X; Yang FC; Robertson KA; Ingram DA; Blakeley JO; Clapp DW
Pediatr Blood Cancer; 2020 Aug; 67(8):e28372. PubMed ID: 32459399
[TBL] [Abstract][Full Text] [Related]
12. [Unusual clinical manifestations of type 1 neurofibromatosis].
Komlósi K; Polgár N; Hadzsiev K; Ottóffy G; Illés T; Dóczi T; Melegh B
Orv Hetil; 2011 Dec; 152(49):1965-70. PubMed ID: 22106164
[TBL] [Abstract][Full Text] [Related]
13. Neurofibromatosis Type 1: Review and Update on Emerging Therapies.
Karaconji T; Whist E; Jamieson RV; Flaherty MP; Grigg JRB
Asia Pac J Ophthalmol (Phila); 2019; 8(1):62-72. PubMed ID: 30387339
[TBL] [Abstract][Full Text] [Related]
14. Location, symptoms, and management of plexiform neurofibromas in 127 children with neurofibromatosis 1, attending the National Complex Neurofibromatosis 1 service, 2018-2019.
Collins-Sawaragi YC; Ferner R; Vassallo G; De Agrò G; Eccles S; Cadwgan J; Hargrave D; Hupton E; Eelloo J; Lunt L; Tang V; Burkitt Wright E; Lascelles K
Am J Med Genet A; 2022 Jun; 188(6):1723-1727. PubMed ID: 35178860
[TBL] [Abstract][Full Text] [Related]
15. Treatment for plexiform neurofibromas in patients with NF1.
Ardern-Holmes SL; North KN
Lancet Oncol; 2012 Dec; 13(12):1175-6. PubMed ID: 23099008
[No Abstract] [Full Text] [Related]
16. Ipsilateral Sphenoid Wing Dysplasia, Orbital Plexiform Neurofibroma and Fronto-Parietal Dermal Cylindroma in a Patient with Segmental Neurofibromatosis.
Friedrich RE; Hagel C; Mautner VF
Anticancer Res; 2015 Dec; 35(12):6813-8. PubMed ID: 26637901
[TBL] [Abstract][Full Text] [Related]
17. New Frontiers in Therapy of Peripheral Nerve Sheath Tumors in Patients With Neurofibromatosis Type 1: Latest Evidence and Clinical Implications.
Marjanska A; Galazka P; Wysocki M; Styczynski J
Anticancer Res; 2020 Apr; 40(4):1817-1831. PubMed ID: 32234870
[TBL] [Abstract][Full Text] [Related]
18. NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Park HJ; Lee SJ; Sohn YB; Jin HS; Han JH; Kim YB; Yim H; Jeong SY
Int J Oncol; 2013 Feb; 42(2):657-66. PubMed ID: 23292448
[TBL] [Abstract][Full Text] [Related]
19. Molecular profiles of neurofibromatosis type 1-associated plexiform neurofibromas: identification of a gene expression signature of poor prognosis.
Lévy P; Bièche I; Leroy K; Parfait B; Wechsler J; Laurendeau I; Wolkenstein P; Vidaud M; Vidaud D
Clin Cancer Res; 2004 Jun; 10(11):3763-71. PubMed ID: 15173083
[TBL] [Abstract][Full Text] [Related]
20. NF1 truncating mutations associated to aggressive clinical phenotype with elephantiasis neuromatosa and solid malignancies.
Ponti G; Martorana D; Pellacani G; Ruini C; Loschi P; Baccarani A; De Santis G; Pollio A; Neri TM; Mandel VD; Maiorana A; Maccio L; Maccaferri M; Tomasi A
Anticancer Res; 2014 Jun; 34(6):3021-30. PubMed ID: 24922668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
